title: Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
abstract: The associations of CD4 cell count, plasma human immunodeficiency virus (HIV) type 1 RNA, infectious HIV titer in peripheral blood mononuclear cells, immune complex-disrupted (ICD) p24 antigen, and MT-2 assays with measures of disease progression after drug treatment were assessed in a subset of patients enrolled in AIDS Clinical Trials Group Study 175. Baseline plasma RNA levels and changes in RNA values at weeks 8 or 56 were more important predictors of disease progression than were baseline or changes in CD4 cell counts. Each 10-fold lower HIV RNA concentration at baseline and each 10-fold decrease in HIV RNA between baseline and week 8 was associated with increases of 49-61 CD4 cells/mm3 at weeks 56 and 104. In multivariate analyses, neither baseline values nor changes in infectious HIV titer nor ICD p24 antigen concentrations were associated with long-term changes in CD4 cell count. Plasma HIV-1 RNA appears to be the best predictor of long-term CD4 cell count responses and disease progression.
authors.affiliation: Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, 27599-7140, USA. sfiscus@email.unc.edu
authors.forename: S A
authors.initials: SA
authors.lastname: Fiscus
authors.forename: M D
authors.initials: MD
authors.lastname: Hughes
authors.forename: J L
authors.initials: JL
authors.lastname: Lathey
authors.forename: T
authors.initials: T
authors.lastname: Pi
authors.forename: B
authors.initials: B
authors.lastname: Jackson
authors.forename: S
authors.initials: S
authors.lastname: Rasheed
authors.forename: T
authors.initials: T
authors.lastname: Elbeik
authors.forename: R
authors.initials: R
authors.lastname: Reichman
authors.forename: A
authors.initials: A
authors.lastname: Japour
authors.forename: R
authors.initials: R
authors.lastname: Byington
authors.forename: W
authors.initials: W
authors.lastname: Scott
authors.forename: B P
authors.initials: BP
authors.lastname: Griffith
authors.forename: D A
authors.initials: DA
authors.lastname: Katzenstein
authors.forename: S M
authors.initials: SM
authors.lastname: Hammer
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015415:Biomarkers; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D018450:Disease Progression; D016655:HIV Core Protein p24 / Q000097:blood*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology*; D015497:HIV-1; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D015999:Multivariate Analysis; D011379:Prognosis; D012367:RNA, Viral / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016047:Zalcitabine / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers; D015224:Dideoxynucleosides; D016655:HIV Core Protein p24; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine